Literature DB >> 2868851

Peptide characterization of secretin preparations.

M M Wolfe, J E Howard, B E Kolts, J E McGuigan.   

Abstract

The present study was designed to examine and compare the peptide composition and relative immunochemical purity of GIH and Boots secretin preparations. Gastrointestinal peptides were measured by radioimmunoassay using antibodies to secretin, gastrin, immunoreactive cholecystokinin, vasoactive intestinal peptide, gastric inhibitory peptide, and somatostatin. Boots secretin was found to contain substantial quantities of gastrin, immunoreactive cholecystokinin, vasoactive intestinal peptide, gastric inhibitory peptide, and somatostatin. In contrast, GIH secretin contained only a very small amount of vasoactive intestinal peptide. GIH also contained approximately three to four times more secretin per unit as did Boots secretin. Intravenous infusion of Boots, but not GIH, secretin in seven healthy volunteers produced significant increases in venous plasma of all peptides. Results of these studies indicate that Boots secretin contains large and variable quantities of gastrointestinal peptides other than secretin and that the contents of both secretin and the other peptides vary among different lots. Because the quantity of these peptides is sufficient to increase significantly their blood levels and consequent biological effects, it is concluded that GIH is preferable to Boots secretin in the clinical evaluation of patients with suspected chronic pancreatitis or gastrinoma.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2868851     DOI: 10.1007/bf01318116

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  17 in total

1.  Preparation of iodine-131 labelled human growth hormone of high specific activity.

Authors:  W M HUNTER; F C GREENWOOD
Journal:  Nature       Date:  1962-05-05       Impact factor: 49.962

2.  Production and evaluation of antibodies for the radioimmunoassay of gastrin.

Authors:  J F Rehfeld; F Stadil; B Rubin
Journal:  Scand J Clin Lab Invest       Date:  1972-10       Impact factor: 1.713

3.  Secretin injection test in the diagnosis of gastrinoma.

Authors:  J E McGuigan; M M Wolfe
Journal:  Gastroenterology       Date:  1980-12       Impact factor: 22.682

4.  Radioimmunoassay measurement of secretin half-life in man.

Authors:  B E Kolts; J E McGuigan
Journal:  Gastroenterology       Date:  1977-01       Impact factor: 22.682

5.  Inhibition of gastrin release by secretin is mediated by somatostatin in cultured rat antral mucosa.

Authors:  M M Wolfe; G M Reel; J E McGuigan
Journal:  J Clin Invest       Date:  1983-11       Impact factor: 14.808

6.  False-positive serum gastrin elevation during secretin stimulation due to Boots secretin.

Authors:  C E Brady; R C Johnson; J R Williams; K Boran
Journal:  J Clin Gastroenterol       Date:  1983-06       Impact factor: 3.062

7.  Circulating levels of vasoactive intestinal polypeptide in liver disease.

Authors:  S Hunt; C A Vaamonde; T Rattassi; G Berian; S I Said; S Papper
Journal:  Arch Intern Med       Date:  1979-09

8.  Effects of glucagon, secretin, and vasoactive intestinal polypeptide on gastric somatostatin and gastrin release from isolated perfused rat stomach.

Authors:  T Chiba; T Taminato; S Kadowaki; H Abe; K Chihara; Y Seino; S Matsukura; T Fujita
Journal:  Gastroenterology       Date:  1980-07       Impact factor: 22.682

9.  Central nervous system inhibition of gastric secretion in the rat by gastrin-releasing peptide, a mammalian bombesin.

Authors:  Y Taché; W Marki; J Rivier; W Vale; M Brown
Journal:  Gastroenterology       Date:  1981-08       Impact factor: 22.682

10.  Immunochemical characterization of gastrinlike and cholecystokininlike peptides released in dogs in response to a peptone meal.

Authors:  M M Wolfe; J E McGuigan
Journal:  Gastroenterology       Date:  1984-08       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.